RedHill Biopharma (RDHL) Research & Development (2012 - 2023)

RedHill Biopharma (RDHL) has reported Research & Development for 12 consecutive years, with $1.2 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Research & Development fell 15.29% year-over-year to $1.2 million in Q2 2023; TTM through Jun 2023 was $5.1 million, a 68.71% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, up 27.39% from the prior year.
• Research & Development was $1.2 million for Q2 2023 at RedHill Biopharma, up from $1.1 million in the prior quarter.
• Over five years, Research & Development peaked at $10.3 million in Q2 2021 and troughed at $1.1 million in Q1 2023.
• A 5-year average of $4.1 million and a median of $3.1 million in 2020 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 221.34% in 2021 and plunged 85.75% in 2022, its largest moves.
• Over 5 years, Research & Development stood at $2.3 million in 2019, then surged by 171.92% to $6.2 million in 2020, then declined by 5.19% to $5.9 million in 2021, then sank by 80.69% to $1.1 million in 2022, then advanced by 10.06% to $1.2 million in 2023.
• The last three Research & Development figures came in at $1.2 million (Q2 2023), $1.1 million (Q1 2023), and $1.1 million (Q4 2022), per Business Quant data.